Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Higher abundance of <i>Faecalibacterium prausnitzii</i> in the gut microbiome is associated with a lower risk of sepsis development among 6,372 individuals followed for 20 years.

mSystems·2026
Same author

Bottom-up self-synthesis of supramolecular Pickering emulsions by interfacial dynamic combinatorial chemistry.

Journal of colloid and interface science·2026
Same author

Tissue-resident neutrophils serve homeostatic and immunological functions in embryos.

Nature communications·2026
Same author

Acute Finnish sauna heat exposure induces stronger immune cell than cytokine responses.

Temperature (Austin, Tex.)·2026
Same author

Macrophage Polarization and Spatial Architecture Characterize the Tumor Immune Microenvironment and Prognosis in Hepatoblastoma.

The American journal of pathology·2026
Same author

Longitudinal association of circulating inflammatory biomarkers with epigenetic ageing in the Young Finns Study.

Scientific reports·2026

Related Experiment Video

Updated: May 21, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Host CD73 impairs anti-tumor immunity.

Marko Salmi1, Sirpa Jalkanen

  • 1MediCity Research Laboratory; University of Turku; Turku, Finland ; Department of Medical Biochemistry and Genetics; University of Turku; Turku, Finland ; National Institute of Health and Welfare; Tykistökatu; Turku, Finland.

Oncoimmunology
|June 22, 2012
PubMed
Summary
This summary is machine-generated.

CD73 enzyme activity creates immune-suppressing adenosine, hindering anti-tumor responses. Inhibiting CD73 in hosts reduces tumor growth and immune suppression, boosting anti-cancer immunity.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Related Experiment Videos

Last Updated: May 21, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • CD73 is an enzyme crucial in purinergic signaling.
  • Its activity generates adenosine, a molecule known to suppress immune responses.
  • Tumor microenvironments often exhibit elevated CD73 expression, contributing to immune evasion.

Purpose of the Study:

  • To investigate the role of CD73 in anti-tumor immunity.
  • To determine the effects of CD73 deficiency and pharmacological inhibition on tumor progression.
  • To elucidate the impact of host CD73 expression on immune cell infiltration in tumors.

Main Methods:

  • Comparative analysis of tumor growth in CD73-deficient and wild-type mice.
  • Assessment of tumor-infiltrating immune cells, including regulatory T cells (Tregs) and M2 macrophages.
  • Pharmacological inhibition of CD73 activity in wild-type mice models.
  • Evaluation of anti-tumor immune responses.

Main Results:

  • CD73-deficient hosts exhibited reduced tumor growth.
  • Tumor infiltration by Tregs and type 2 immunosuppressive macrophages was decreased in CD73-deficient hosts.
  • Pharmacological inhibition of CD73 in wild-type mice mirrored these tumor-suppressing effects.
  • Host CD73 expression on leukocytes and endothelial cells was found to be detrimental to anti-tumor immunity.

Conclusions:

  • Host CD73 enzymatic activity promotes tumor growth by producing immune-suppressive adenosine.
  • Targeting CD73, either genetically or pharmacologically, can enhance anti-tumor immunity.
  • CD73 represents a potential therapeutic target for cancer immunotherapy.